BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Hong Kong

Ascletis Pharma Inc. Advances Oral GLP 1 And Amylin Combination For Obesity Treatment

-Fixed-dose combination of ASC30 and ASC39 (ASC30_39 FDC) tablets, dosed orally in dogs, demonstrated comparable pharmacokinetics to those observed in...

April 09, 2026 | News

Alphamab Oncology Reports Phase III Success For Anbenitamab In HER2 Positive Breast Cancer

Alphamab Oncology announced that HER2 bispecific antibody Anbenitamab Injection (KN026), independently developed by the Company, and co-developed wit...

April 06, 2026 | News

Abbisko Therapeutics Secures FDA IND Clearance For ABSK061 In Achondroplasia

Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256.HK) announced that the U.S. Food and Drug Administration has cleare...

April 01, 2026 | News

Everest Medicines Acquires CARDAMYST Rights To Strengthen Cardiovascular Portfolio In Greater China

Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, a...

March 24, 2026 | News

Belief BioMed And Grand Life Sciences Forge Exclusive Pact To Advance Hemophilia A Gene Therapy

Belief BioMed ("BBM") and Grand Life Sciences Group Co., Ltd. ("Grand Life Sciences") today announced an exclusive collaboration agreement. Under the agree...

March 24, 2026 | News

Alphamab Oncology Initiates Phase 3 Study Of Bispecific ADC JSKN016 In Triple Negative Breast Cancer

Alphamab Oncology announced that the first patient has been dosed in a phase III clinical study (JSKN016-301) evaluating JSKN016, a novel TROP2/HER3 bispec...

March 23, 2026 | News

Innorna Secures FDA Clearance For First In Class mRNA Therapy IN026 In Refractory Gout

IN026 is a potential first-in-class mRNA therapy for refractory gout, marking the emergence of a new category of mRNA medicines enabled by Innorna's propri...

March 19, 2026 | News

Alphamab Oncology Doses First Patient In Global Phase I Trial Of First PD L1 VEGFR2 Bispecific ADC

Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed in the phase I clinical study (study code: JSKN027-101...

March 18, 2026 | News

Akeso Secures China IND Clearance For First In Class Trispecific Antibody AK150 Targeting Solid Tumours

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that its proprietary first-in-class trispecific antibody, AK150 (ILT2/ILT4/CSF1R), has rec...

March 17, 2026 | News

Hong Kong Approves Ohtuvayre For COPD Maintenance Treatment Under 1 Plus Regulatory Pathway

Approval marks the second regulatory approval outside of the U.S. Food and Drug Administration, further expanding access to COPD patients in select Special...

March 16, 2026 | News

Alphamab Oncology IND For Dual Payload Bispecific ADC JSKN021 Accepted By China NMPA

Alphamab Oncology (stock code: 9966.HK) announced that the Investigational New Drug (IND) application for JSKN021, an independently developed innovative du...

March 16, 2026 | News

Codex Genetics And C2N Diagnostics Partner To Expand Alzheimer’s Blood Test Access In Hong Kong

Codex Genetics, a leading precision diagnostics company headquartered in Hong Kong, today announces a strategic collaboration with C2N Diagnostics (C2N), a...

March 11, 2026 | News

Ascletis Reports Positive Phase II Results For Monthly ASC30 Injection In Obesity Treatment

- ASC30 subcutaneous (SQ) depot formulation achieved statistically significant and clinically meaningful placebo-adjusted mean weight loss of ...

March 11, 2026 | News

Akeso Reports Durable Long Term Survival Benefit Of Cadonilimab In Advanced Cervical Cancer

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the latest long-term survival analysis data from the China pivotal registrational Phase II ...

March 06, 2026 | Report

Stay Connected